Generic Medications

Generic RAVICTI® Options – Live Updates

FDA Approval & Endo Announcement

October 20, 2025, Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced the launch of a generic version of RAVICTI® (1.1 gm/mL oral liquid). Availability and pricing details not yet provided. Read the full announcement. The community reports that switching from Ravicti® to the generic version offered by Endo has resulted in a cost reduction of approximately 10–15%.

Lupin Launches Authorized Generic Version of Ravicti® in the United States

Mumbai, Naples, October 24, 2025: Global pharma major Lupin Limited (Lupin) today announced the launch of an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States. Read the full announcement. Based on current information, Lupin is expected to enter the market following an exclusivity period for Endo’s product.

Lupin Savings Program

Report Issues with Generic GPB transition

NUCDF continues to monitor the community’s transition to generic glycerol phenylbutyrate and is collecting feedback to inform our ongoing advocacy efforts. Please complete the form below to share your experience.

Philanthropic Initiative

In addition, as previously announced at the 2025 NUCDF Family Conference, a separate, fully funded philanthropic initiative to develop an affordable and accessible generic option is also underway.

Updates will be posted to this page as more information becomes available.

NUCDF Support & Updates

In alignment with our mission, NUCDF remains dedicated to supporting all initiatives that enhance access. Our goal is to ensure that patients will have consistent and affordable access to this essential medication. We will continue to seek and share the latest information on this topic as it becomes available.